MDxHealth SA (MDXH)

Market Cap	104.78M +46.7%
Revenue (ttm)	107.88M +19.8%
Net Income	-33.52M
EPS	-0.67
Shares Out	51.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	204,274
Open	2.100
Previous Close	2.070
Day's Range	2.000 - 2.230
52-Week Range	1.395 - 5.330
Beta	-537,510.36
Analysts	Strong Buy
Price Target	7.67 (+276.9%)
Earnings Date	May 14, 2026

About MDXH

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies pe...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 4, 2021
• Employees: 312
• Stock Exchange: NASDAQ
• Ticker Symbol: MDXH
• Website: https://mdxhealth.com

Financial Performance

In 2025, MDxHealth's revenue was $107.88 million, an increase of 19.80% compared to the previous year's $90.05 million. Losses were -$33.52 million, -11.95% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for MDXH stock is "Strong Buy." The 12-month stock price target is $7.67, which is an increase of 276.90% from the latest price.

Price Target

$7.67

(276.90% upside)

Analyst Consensus: Strong Buy